The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects

The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects

2021 Drug discovery today

Qiu, Tingting | Wang, Yitong | Liang, Shuyao | Han, Ru | Toumi, Mondher | Volume: , Issue: , Pages: S1359-6446(21)00207-5, COVID-19, Cell and gene therapies, Health technology assessment, Regulatory,

Coronavirus 2019 (COVID-19) has caused significant disruption to the cell and gene therapy (CGT) industry, which has historically faced substantial complexities in supply of materials, and manufacturing and logistics processes. As decision-makers shifted their priorities to COVID-19-related issues, the challenges in market authorisation, and price and reimbursement of CGTs were amplified. Nevertheless, it is encouraging to see that some CGT developers are adapting their efforts toward the development of promising COVID-19-related therapeutics and vaccines. Manufacturing resilience, digitalisation, telemedicine, value-based pricing, and innovative payment mechanisms will be increasingly harnessed to ensure that market access of CGTs is not severely disrupted.

https://www.doi.org/10.1016/j.drudis.2021.04.020